INTERVIEWS

Over 200,000 cosmetic procedures were performed on teens last year. Board Certified Facial Plastic Surgeon, Dr. Demetri Arnaoutakis discusses why we are seeing an increase in teens, ages 13 to 19, getting plastic surgery and the dangers associated with it.

New CEO of Squarex, Jack V. Talley discusses the positive results of the phase 2 study on their new investigational drug candidate SQX770, a topical immunomodulator treatment to extend the time between herpes labialis (recurrent cold sores) outbreaks caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2.  Squarex is a clinical-stage pharmaceutical company.

Dr. Doug Manion, CEO of Kleo Pharmaceuticals, discusses his personal journey from working as an engineer in Africa to going to med school and then moving into drug development.

Kleo Pharmaceuticals is a unique immuno-oncology company poised to solve some of the problems dominating the headlines for the biopharmaceutical industry. CEO Dr. Doug Manion discusses the development of next-generation bispecific compounds designed to emulate or enhance the activity of biologics, which directly engage patients’ immune systems to target and destroy cancer cells. Human studies are anticipated in 2020.

September is Infant Mortality Awareness Month and returning guest Manuel Fermin, CEO of the Healthy Start Coalition discusses infant mortality and ways in which to address the issue and reduce high infant mortality rates.

Dr. Kate Mangione discusses a study recently published in JAMA that looked at the effects of home-based physical therapy on elderly hip fracture patients.

Dr. Rebecca Craik, dean of the College of Health Sciences at Arcadia University discusses a study recently published in JAMA (Sept 2019) in which she was co-PI, that looked at the effects of home-based physical therapy on elderly hip fracture patients.  The study shows that more rigorous physical therapy than what is usually offered can help return the patient to their “before” lifestyle.

Dr. Jerry Silver, Professor of Neurosciences at Case Western Reserve University’s School of Medicine and advisor to NervGen Pharma, discusses NervGen Pharma’s spinal cord regeneration technology. In animal studies an injectable peptide, developed by Dr. Silver and NervGen, allowed paralyzed rats to walk again. Phase 1 clinical trials are on the horizon in 2020.

Dr. Amit Kumar discusses the partnership with the Cleveland Clinic to develop an experimental vaccine for breast cancer.

John Termini recently presented his finding at the American Chemical Society annual meeting about how diabetes increases cancer risks.